Nacubactam

A beta-lactamase inhibitor used in combination with antibiotics

Nacubactam
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Nacubactam is a novel beta-lactamase inhibitor that is being developed for use in combination with beta-lactam antibiotics to combat antibiotic resistance. It is particularly effective against Gram-negative bacteria that produce beta-lactamase enzymes, which are responsible for breaking down beta-lactam antibiotics and rendering them ineffective.

Mechanism of Action

Nacubactam works by inhibiting the activity of beta-lactamase enzymes. These enzymes are produced by certain bacteria as a defense mechanism against beta-lactam antibiotics, such as penicillins and cephalosporins. By inhibiting these enzymes, nacubactam restores the efficacy of beta-lactam antibiotics, allowing them to target and kill the bacteria.

Clinical Development

Nacubactam is currently undergoing clinical trials to assess its safety and efficacy in combination with various beta-lactam antibiotics. It is being studied for the treatment of serious infections caused by multi-drug resistant Gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.

Combination Therapy

Nacubactam is often combined with cefepime, a fourth-generation cephalosporin, to enhance its antibacterial activity. This combination is being evaluated for its potential to treat complicated urinary tract infections, hospital-acquired bacterial pneumonia, and other serious infections.

Advantages

The use of nacubactam in combination with beta-lactam antibiotics offers several advantages:

• Broad Spectrum of Activity: It extends the spectrum of activity of beta-lactam antibiotics against resistant strains.
• Reduced Resistance Development: By inhibiting beta-lactamase, nacubactam reduces the likelihood of resistance development.
• Enhanced Efficacy: It enhances the overall efficacy of the antibiotic regimen, leading to better clinical outcomes.

Challenges

Despite its potential, the development of nacubactam faces several challenges:

• Regulatory Approval: It must undergo rigorous clinical trials to gain regulatory approval.
• Cost: The development and production costs may impact its accessibility and affordability.
• Resistance: There is always a risk of bacteria developing resistance to new inhibitors over time.

Related Pages

• Beta-lactamase
• Antibiotic resistance
• Cefepime
• Gram-negative bacteria